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Abstract
Purpose: Standard dose of external beam radiotherapy seems to be insufficient for satisfactory control of
loco-regionally advanced cervical cancer. Aim of our study is to evaluate the outcome as well as early and
chronic toxicities in patients with loco-regionally advanced cervical cancer, treated with dose escalated
intensity modulated radiotherapy (IMRT) combined with cisplatin chemotherapy.
Material and methods: Thirty-nine patients with cervical carcinoma FIGO stage IB2 – IVA were treated with
curative intent between 2006 and 2010. The dose of 50.4 Gy was prescribed to the elective pelvic nodal
volume. Primary tumors < 4 cm in diameter (n = 6; 15.4 %) received an external beam radiotherapy (EBRT)
boost of 5.4 Gy, primary tumors > 4 cm in diameter (n = 33; 84.6 %) received an EBRT boost of 9 Gy. Patients
with positive lymph nodes detected with 18FDG-PET/CT (n = 22; 56.4 %) received a boost to a total dose of
59.4 - 64.8 Gy. The para-aortic region was included in the radiation volume in 8 (20.5 %) patients and in 5
(12.8 %) patients the para-aortic macroscopic lymph nodes received an EBRT boost. IMRT was followed with a
3D planned high dose rate intrauterine brachytherapy given to 36 (92.3 %) patients with a total dose ranging
between 15–18 Gy in three fractions (single fraction: 4–6.5 Gy). Patients without contraindications (n = 31/79.5 %)
received concomitantly a cisplatin-based chemotherapy (40 mg/kg) weekly. Toxicities were graded according to the
common terminology criteria for adverse events (CTCAE v 4.0).
Results: Mean overall survival for the entire cohort was 61.1 months (±3.5 months). Mean disease free survival
was 47.2 months (±4.9 months) and loco-regional disease free survival was 55.2 months (±4.4 months). 65 %
of patients developed radiotherapy associated acute toxicities grade 1, ca. 30 % developed toxicities grade 2
and just two (5.2 %) patients developed grade 3 toxicities, one acute diarrhea and one acute cystitis. 16 % of
patients had chronic toxicities grade 1, 9 % grade 2 and one patient (2.6 %) toxicities grade 3 in the form of
vaginal dryness.
Conclusion: Dose escalated IMRT appears to have a satisfactory outcome with regards to mean overall
survival, disease free and loco-regional disease free survival, whereas the treatment-related toxicities
remain reasonably low.
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Introduction
The last major advancement in the treatment of cervical
cancer was made more than 15 years ago. Several large
prospective randomized clinical trials have shown that the
combination of radiotherapy with chemotherapy prolongs
the disease-free survival while also reducing mortality.
Even though the outcome of radio-chemotherapy is better
than that of radiation alone, the combined regimen was
associated with a higher incidence of side effects while
loco-regional control and overall survival still remained
unsatisfactory [1–4]. Between twenty to forty percent of
patients treated with conventional radiotherapy will re-
lapse loco-regionally, not only outside of the treatment
field but also within the treated volume [5]. Unfortunately,
the prognosis for these patients is very poor with only a
few therapeutic options available such as pelvic exenter-
ation or palliation. The reasons for the loco-regional
failure may be attributed to geographical target miss,
insufficient dose of radiation delivered to the primary
tumor and/or to the nodal area [5, 6].
At the same time, a rapid development of the radiation
delivery machines and cancer imaging has been
achieved. These changes are well-mirrored in a signifi-
cantly improved therapeutic ratio of IMRT for various
tumor entities, including cervical cancer [7]. External
beam dose escalation results in more favorable treatment
outcome while the incidence of radiation induced
toxicities, early and chronic, is sinking. Incorporation of
multimodal imaging, especially in patients with cervical
cancer, enhances the detection of nodal or systemic dis-
ease, and leads to a better definition of local disease [6].
However the level of evidence in the utilization of
IMRT and of new imaging modalities, in the treatment
of gynecological malignancies is still low. There is cur-
rently only one phase II prospective randomized trial,
comparing conventional radiotherapy to IMRT, with
published results [8]. In the available literature, there are
many suggestions and different approaches in the treat-
ment of cervical cancer using highly conformal radio-
therapy and yet there is still no well-defined concept
concerning the required total dose, the volume and the
required constraints. Furthermore, even though there is
a known potential benefit on quality of life, as well as a
favorable toxicity profile of IMRT compared to 3D
conformal radiotherapy, there is still an ongoing debate
about its general use in gynecological cancer. In addition,
there is still not enough data available, concerning the
possibility of dose escalation using external beam radio-
therapy for the treatment of both the primary tumor as
well as nodal disease [9].
In 2006, our group began using IMRT as a standard
radiation delivery method for cervical cancer patients.
Our treatment concept was based on usage of escalated
external beam radiotherapy dosage for treating the
infiltrated regional lymph nodes and of the primary
tumor compared to the standard dosage (45-50Gy). We
conducted this retrospective study in order to evaluate
the treatment-related toxicities, early and chronic, as
well as the clinical outcome of cervical cancer patients
treated with escalated dose of IMRT.
Material and methodes
Patients
Patients with histologically confirmed cervical cancer,
FIGO stage IBII to IVA, treated with IMRT at the Bern
University Hospital Department of Radiation Oncology
were included in this retrospective study according to
the institutional ethical standards. We evaluated all
medical and radiotherapy records, pretreatment and
follow-up images of 39 patients treated between October
2006 and January 2011. Patient characteristics are summa-
rized in Table 1. Median follow-up time was 35 months.
Before treatment all patients underwent pretreatment
staging workup, including medical history, general phys-
ical and gynecological examination, digital rectal examin-
ation, tumor biopsy, comprehensive laboratory analysis
and in cases of suspected rectal or bladder infiltration,
additional rectoscopy and cystoscopy. The primary tumor
Table 1 Patient characteristic
Age at time of diagnosis: median (range) 59.5 year (range: 26 to 89)
No. %
FIGO stage
IB2 4 10.3
IIA 2 5.1
IIB 20 51.3
IIIB 9 23.1
IVA 4 10.3
Size of primary tumors
Tumors < 4 cm 6 15.4
Tumors > 4 cm 33 84.6
Lymph nodes status
N0 15 38.5
N1 24 61.5
Paraaortic Positive LN 5 12.8
Median number of positive LN per patient 2.5 (range: 1 to 5)
Tumor histology
No %
Adenocarcinoma 9 23.1
Squamous Cell Carcinoma 30 76.9
Tumor grade
Grade 1 1 2.6
Grade 2 25 64.1
Grade 3 13 33.3
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was clinically assessed by an experienced gynecologist and
radiation oncologist. Tumor staging was defined accord-
ing to the International Federation of Obstetrics and
Gynecology (FIGO) and the TNM-UICC system. In
addition, local tumor extension was assessed by MRI, but
the initial tumor stage was not influenced by the findings.
All patients with cervical cancer clinically staged as IB2-
IIB underwent pretreatment staging with 18FDG-PET/CT
scan. If the PET-CT revealed, clear signs of metastatic
lymph nodes, the patients were selected for definitive
radio-/chemotherapy. In case of negative PET-CT
findings, patients were selected for surgery, were a
sentinel lymph node dissection was performed with
frozen section pathological evaluation. If the sentinel
lymphadenectomy revealed positive lymph nodes, or
an advanced tumor stage was intraoperatively de-
tected, the surgery was stopped and the patients were
referred for definitive radio-/chemotherapy. If the
sentinel lymphadenectomy revealed no positive lymph
nodes, a complete surgery was performed, including a
paraaortal lymphadenectomy. Any further therapy
decisions were made in a multidiscipline tumor board
setting after complete pathological evaluation. Patients
with clinical stage FIGO IIB or greater were selected
for radio-chemotherapy. In cases with doubtful or
suspicious findings regarding lymph node status those
were surgically evaluated.
At the beginning of 2010 our policy was changed
regarding surgical staging, and all patients, regardless of
tumor stage, were surgically evaluated (n = 11). Two
(5.1 %) patients have positive lymph nodes that were not
previously detected by imaging and 3 (7.7 %) patients
have advanced local tumor extension. These patients
subsequently received definitive radio-chemotherapy.
Information on surgery and concomitant therapy data
are shown in Table 2.
Radiotherapy planning: treatment volumes and dose
prescription
All patients underwent a planning computer tomog-
raphy (CT) without contrast in supine position.
Patients were instructed to come for the planning CT
as well as the daily radiotherapy fractions with a full
bladder. No particular instructions were given re-
garding rectal filling. The CT slice thickness was
3 mm. A personalized adjusted immobilization device
was created for each patient.
Image sets acquired by CT, diagnostic 18FDG-PET/CT
and MRI were imported into the Eclipse Planning
System (Varian Medical System, Palo Alto, CA). We
used the “automatic matching algorithm”, with manual
correction as needed. Registration quality was regarded
as acceptable, when bony structure misalignment did
not exceed </=1 mm. External beam radiotherapy was
delivered using a dynamic multi-leaf linear accelerator
with a photon energy of 6 MV.
The gross tumor volume of the cervix (GTVc) was
defined as the visible macroscopic tumor based on all
the available clinical and imaging data. Clinical target
volume for primary tumor area (CTVc) encompassed
GTVc, uterus, parametria and the upper third of the
vagina. In cases of vaginal involvement, CTVc expanded
2 cm into the vagina caudally of the tumor. The plan-
ning target volume of primary tumor (PTVc) was
created using anisotropic expansion, considering cervical
and surrounding structure movements. The PTVc was
expanded to 15 mm in the antero-dorsal direction and
10 mm in the lateral direction. PTVc was manually
corrected if needed. The asymmetrical margin for PTV
was chosen based on the fact, that in cervical cancer,
movement is not uniform in all directions [10]. In the
dorsal direction PTVc margin extended maximally to
the posterior rectal wall and in frontal direction
maximally 1.5 cm into the bladder.
In the first phase PTVc was irradiated with a total
dose of 50.4 Gy. After 45 Gy a control MRI was
performed to evaluate tumor response and measure
tumor size. In cases where the remaining tumor was
larger than 4 cm in diameter, an additional EBRT
boost of 9 Gy was administered to the PTVc. Other-
wise, for tumors smaller than 4 cm in diameter, the
PTVc was irradiated with an EBRT boost of 5.4 Gy.
Single dose was 1.8 Gy.
Table 2 Therapy data
Surgery and concomitant therapy
n %
Patients with incomplete (primary) surgery 4 10.3
Patients with surgical nodal staging 11 28.2
Clinical nodal staging 28 71.8
Complete chemotherapy
(Cisplatin 40 mg/m2 weekly)
31 79.5
Patients without all cycles of chemotherapy
due to hematological toxicities
3 7.7
Patients without chemotherapy due
to contraindication or refusal
5 12.8
Radiotherapy dosage
Median (Gy) Range (Gy)
Radiotherapy duration (days) 60 46 - 96
EBRT elective pelvic nodal dose (Gy) 50.4 45-55.8
EBRT elective paraaortral dose (Gy) 47.7 45 - 50.4
EBRT Tumor Boost dose (Gy) 9 5.4 - 21.6
EBRT Total Tumor Dose (Gy) 59.4 50.4 - 72
LN Boost dose (Gy) 62 59.4 - 64.8
Brachytherapy total dose (Gy) 18 10 - 24
Brachytherapy single dose (Gy) 6 5-6
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Nodal PTV and SIB volume
The elective clinical target lymph nodes (LN) volume
encompassed the common, external and internal iliac
lymphatic chain to the aortic bifurcation and presacral
LN area. In case of LN involvement at the level of the
common artery or aortic LN, we extended the elective
nodal volume to the level of the renal arteries. A safety
margin of 7 mm was added to define the nodal planning
target volume (PTVn). PTVc and PTVn were merged to
one single planning target volume (PTVsum).
Nodal gross tumor volume (GTVn) was based on data
acquired by 18FDG-PET/CT including assessment of
other imaging modalities (CT, MRI). Positive LNs were
delineated separately as nodal gross tumor volume
(GTVn). PTVn boost was formed by adding a safety
margin of 5 mm to the GTVn. A total of 22 (56.4 %)
patients were given a nodal boost, 12 (30.8 %) with
consecutive and 10 (25.6 %) with simultaneous inte-
grated boost (SIB). Rational and methods for SIB
delivery are described in our previous work [11].
An example of a treatment plan is shown in Fig. 1.
Constraints for organs at risk
Organs at risk were delineated on the axial CT slices.
We delineated the rectum up to the sigmoid. The bowel
was contoured to the level extending one vertebral body
beyond the upper border of the PTV, including large
and small intestines. The bladder and femoral heads
were also contoured. Dose constraints for organs at risk
were standardized as follows: 60 % of rectal volume
should receive not more than 50 Gy, 35 % of bowel
volume should receive no more than 35Gy, 50 % of
bladder volume should receive no more than 50 Gy
and 10 % of the femoral heads volume should receive
no more than 50 Gy.
Brachytherapy
EBRT was followed by a HDR boost to the primary tumor
in 36 (92.3 %) patients, administered one week after com-
pletion of EBRT. Brachytherapy consisted of a total dose
between 15 to 18 Gy delivered in 2 to 4 weekly fractions,
with a single dose of 4 to 6.5 Gy. We used a microSelec-
tron® HDRB Unit and a Vienna Ring CT-MRI Applicator
Set. MRI images were evaluated together with our radi-
ology department to define the high and intermediate risk
areas. Afterwards, we reconstructed the high risk and
intermediate risk areas detected in the MRI images on our
planning CT images. Planning volumes were planned
according to the GEC-ESTRO guidelines [12]. Because of
the dose escalation of EBRT we adapted our brachyther-
apy dose constraints as suggested in the ABS guideline
[13]. Three patients (7.7 %) refused the administration of a
brachytherapy boost.
Chemotherapy
Patients were scheduled to receive concomitant cisplatin
based chemotherapy (40 mg/kg) weekly during the full
course of radiotherapy. 31 (79.5 %) patients received the
chemotherapy as planned. The details for the remaining
patients (n: 8, 20.5 %) are listed in Table 2.
Fig. 1 Example of treatment plan
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Toxicities assessment and follow-up
We assessed patients for acute toxicities weekly during
the course of radiotherapy and once 6 weeks after
therapy completion. Toxicities were graded according to
the CTCAE v 4.0. The initial tumor response was evalu-
ated clinically by a gynecological oncologist 3 months
after radiotherapy with a follow up 3 months thereafter
for the next two years, and every 6 months afterwards.
Clinical evaluation includes a PAP smear. We conducted
an 18FDG-PET/CT 6 months after therapy to evaluate
the local control as well for the detection of systemic
metastases, as recommended in the NCCN guidelines.
Failure was defined as persistent disease or tumor
recurrence following radiotherapy. The date of failure
was defined as the date of any signs of disease, either
clinical or by imaging. The site of failure was recorded
as local, nodal (regional) and distant. Furthermore, a
distinction was made between in-volume nodal failures
or “out of volume” nodal failures. Moreover, we distin-
guished between nodal failures in the boost region from
failure in the elective volume.
Statistical consideration
Primary endpoints of interest were overall survival
(OS, time between the first day of radiotherapy to the
date of death, independent of cause, or the date of the
last follow-up), disease-free survival (DFS, time
between the first day of radiotherapy to the date of
any sign of tumor relapse) and loco-regional disease-
free survival (LRDFS, time between the first day of
radiotherapy to the date of any sign of tumor relapse in
the former tumor bed or the nodal CTV region). Differ-
ences in survival time were analyzed using the log-rank or
Wilcoxon’s test and plotted using Kaplan-Meier curves.
P-values <0.05 were considered statistically significant.
All analyses were carried out using SAS (V9.2; The SAS
Institute, Cary, NC).
Results
Recurrence rate and site of recurrence
During follow-up 25 (64.1 %) patients had complete
response three months after therapy and remained
disease free within follow-up. Median follow-up time
was 35.5 months. Fourteen (35.9 %) patients developed a
recurrence. One (2.6 %) patient developed isolated local
relapse and one (2.6 %) patient isolated nodal relapse.
Nine (23.1 %) patient developed loco-regional recidive
[8 (20.5 %) local and 5(12.8 %) nodal]. All but, two
loco-regional recidive was within treated volume. Twelve
(30.8 % of all patients, or 85.7 % of patients with relapse)
patients developed systemic disease. Isolated systemic
disease occurred in 5 (12.8 %) patients.
The pattern of recurrence follows in the majority of
patients the natural course of cervical cancer, where the
loco-regional relapse occurs first, followed by systemic
metastasis in 5 patients. Two patients had simultan-
eously loco-regional and systemic relapse and only 1
patient had systemic metastasis preceding loco-regional
failure. Median time to relapse at any site was 9 months
(range 3 to 38 months), with median time to systemic
metastasis being 12 months (range 3 to 38 months)
and loco-regional metastasis being 9 months (range
5–25 months).
We did not record any failures in the regions of
positive lymph nodes treated with boost (consecutive
or SIB).
Survival time
OS, DFS and LRFS were analysed and stratified by FIGO
stage, tumor grading (G1/G2 versus G3), number of
positive lymph nodes and tumor size (cut-off 4 cm).
In terms of OS (5-year OS was 76.3 %), there was
no association with FIGO stage (p = 0.771), number
of positive lymph nodes (p = 0.9173) or tumor size
(p = 0.301) although a statistically significant differ-
ence was observed in patients with a higher tumor
grading (p = 0.035; Fig. 2a and b).
5-year DFS was 60.3 %. There was no statistically
significant relationship between FIGO stage and DFS
(p = 0.3937) or tumor size (p = 0.283). Patients with
higher tumor grade tended toward a worse DFS than
their low tumor grade counterparts (p = 0.0619, Fig. 2c
and d), while no difference in survival time was found
for patients with a high or low number of affected
lymph nodes (p = 0.3597).
No association of FIGO (p = 0.739), tumor size (p =
0.65), tumor grade (p = 0.778), or lymph node positivity
(p = 0.691) was observed in terms of LRFS (5-year LRFS
was 75.1 %).
Toxicities
There were no acute or chronic toxicities greater than
grade 3 and we did not record any toxicity related treat-
ment breaks.
The most common acute toxicity was diarrhea, re-
corded in 15 (38.5 %) patients, followed by vaginal
mucositis in 12 (30.8 %), cystitis in 9 (23.1 %) and procti-
tis in 7 (17.9 %) patients. The majority of acute side
effects were grade 1 and 2, self-limited or treated with
dietary interventions or symptomatic therapy. One
(2.6 %) patient experienced acute diarrhea grade 3 and
one (2.6 %) acute cystitis grade 3. All acute toxicities
were resolved within 6 weeks after radiotherapy.
The most common chronic toxicity was vaginal stric-
ture recorded in 8 (20.5 %) patients followed by cystitis
in 3 (7.7 %) patients; one (2.6 %) patient developed a
chronic proctitis grade 2. An overview of the acute and
late toxicities is summarized in Table 3.
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Discussion
The experience with IMRT in the treatment of cervical
cancer is limited and there is currently only one phase II
prospective randomized trial, comparing conventional
radiotherapy to IMRT, with published results [8], Even
less is known about external beam dose escalation using
IMRT for this tumor entity.
The outcome and toxicities of conventional external
beam radiotherapy combined with concomitant chemo-
therapy, is well summarized in the meta-analysis of the
Fig. 2 Kaplan-Meier curves of a) overall survival time for the entire cohort followed by b) stratification by tumor grade, c) Disease-free survival
time for the entire cohort and d) stratified by tumor grade (log-rank test)
Table 3 Overview of early and late toxicities
Acute: n (%) Chronic: n (%)
Toxicities grade Small bowel Rectum Bladder Vagina Small bowel Rectum Bladder Vagina
0 24 (61.5) 32 (82.1) 30 (76.9) 27 (69.2) 39(100.0) 38 (97.4) 36 (92.3) 31 (79.5)
1 9 (23.1) 4 (10.3) 6 (15.4) 7 (17.9) 0 (0.0) 0 (0.0) 1 (2.6) 3 (7.7)
2 5(12.8) 3 (7.7) 2 (5.1) 5 (12.8) 0 (0.0) 1 (2.6) 1 (2.6) 4 (10.3)
3 1 (2.6) 0 (0.0) 1 (2.6) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6) 1 (2.6)
4 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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“Meta-Analysis Group, Medical Research Council Clin-
ical Trials Unit” [14]. The group analyzed individual
data from 13 trials, comparing concomitant radio
chemotherapy versus chemotherapy alone in patients
with cervical cancer FIGO stage IB to IVA. Delivered
dose ranged from 40 Gy to 45 Gy to the whole pelvis
with EBRT boost in the primary tumor region up to
61.2 Gy and consecutive low dose rate or HDR
brachytherapy boost from 18 to 50 Gy. The com-
bined regime showed an improvement in the overall
DFS and the loco regional DFS of 8 % and 9 % at
5 years respectively. Disease free survival at 5 years
was 58 %. The benefit in survival was accompanied
by higher rates of serious adverse events including
gastrointestinal toxicities.
Compared to conventional or 3D radiotherapy, IMRT
achieves a better conformity and sparing of normal
tissue. Roeske et al. showed a reduced dose to the small
bowel [15]. Several other authors showed a good target
coverage with a significantly lower dose to the bladder,
rectum, and small bowel [16–18]. Ahmed et al. and
Esthappan et al. introduced a more aggressive approach
for patients with metastatic paraaortic lymph nodes
while sparing risk structures and achieving an acceptable
level of early and chronic unwanted events. Dosimetric
studies were followed by several retrospective analyses,
where authors showed a favorable toxicities profile of
IMRT (Table 4) [19–23].
Traditionally, EBRT whole-pelvic doses are limited to
45 to 50 Gy, primarily due to the small bowel tolerance
as a limiting factor. As already discussed, IMRT has an
improved therapeutic ratio and therefore introduces the
possibility of sparing healthy organs without a com-
promise to the target volume dosage. Incidence of early
grade 3 or higher gastrointestinal (GIT) and urogenital
(UG) toxicities for conventional radio-chemotherapy is
more than 25 % [3, 24]. Compared with conventional
radiotherapy overall incidence of toxicity in our cohort
was low. We did not record any serious adverse event
grade 4 or 5, and despite of the EBRT dose intensifica-
tion, acute toxicities in our patient cohort remain within
reasonable range. A similar incidence of serious adverse
events ranging between 2 % to 4.6 % for acute and 6.4 to
7 % for late toxicities is reported by other authors. A
review of the literature with their corresponding results
is presented in Table 4 [8, 25–31].
In our institution we defined our treatment concept
based on two goals. Firstly, by using an escalated dose
we tried to sterilize the macroscopic metastatic disease
in the lymphatic pathways while reducing the primary
tumor size, which in turn had a benefit for the appli-
cation of the brachytherapy boost. We managed to
achieve treatment results, comparable with results
reported in the literature.
Kidd et al. compared outcome and toxicities of 317
cervical cancer patients treated with step-wedge inten-
sity modulation technique and 135 patients treated with
PET/CT-guided IMRT. The majority of patients were
diagnosed with FIGO IIB and IIIB. 30.4 % and 17.0 % of
patients treated with IMRT were diagnosed with meta-
static pelvic and para-aortic lymph nodes respectively.
The IMRT group showed better disease specific survival
and overall survival [6].
Hasselle et al. treated 81 patients (FIGO IIB-IVA) with
definitive IMRT followed by HDR or LDR brachyther-
apy. The prescription dose for IMRT ranged between
39.6 and 50.4 Gy with median dose of 45 Gy. Three-year
OS and the DFS were 61.4 % and 51.4 %, respectively. The
3-year pelvic failure rate (PF) was 29.2 %. The 3-year
cumulative incidences of PF alone, DF alone, synchronous
PF/DF, and CM as first events were 8.6 %, 10.1 %, 4.8 %,
and 7.0 %, respectively. Six patients had isolated PF,
and five had synchronous PF and DF. For all patients,
the 3-year cumulative incidence of PF was 13.6 %.
Pelvic failure locations included the cervix in 5 patients,
vagina in 4 patients, vulva in 1 patient, and cervix plus
a pelvic lymph node in 1 patient [25].
Chen et al. conducted a retrospective study with 109
patients with cervical cancer (FIGO IB2-IVA). Positive
pelvic LN and PALN were diagnosed in 12.8 % and
11.9 % respectively. IMRT dose given to the GTV ranged
from 45 to 54 Gy with concomitant boost of 54 to 60 Gy
to the involved lymph nodes. The median follow up time
for all surviving patients was 32.5 months, with a range
from 5 to 75 months. The 3-year OS, LFFS (local
failure free survival) and DFS were 78.2 %, 78.1 %
and 67.6 %, respectively [26]. The treatment concept
used, was similar to ours.
The major difference in patient population between
the cited studies and ours is seen in the incidence of
detected nodal metastasis and patients with bulky
tumors > 4 cm. A significantly lower percentage of
patients were diagnosed with metastatic lymph nodes
in contrast to our cohort (61.5 % with lymph nodes
metastases). Even though a review of the available
literature would suggest a worse outcome in lymph
node positive patients, this was not the case in our
patient collective [32]. It could be hypothesized that
an efficient control in the pelvic region contributed to
the overall disease control. An important result of
our study is the fact that we have achieved an excel-
lent control of the metastatic lymph nodes with a
median dose of 62 Gy [range 59.4 to 64 Gy]. During
follow-up, there was no nodal failure detected within
the high dose nodal volume.
However, 8 patients developed loco-regional recidive
within irradiated volume and one patient outside irradi-
ated volume in form of distant vaginal failure. Reasons
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Table 4 Literature overview
Author and year
of publication
Therapy seetings
and study type
IMRT EBRT total dose/
EBRT daily dose
Brachytherapy
total dose
Number of patients
treated with IMRT
FIGO Stage Number of patients
with positive pelvic
lymph nodes
Number of patients
with negative
lymph nodes
Follow-up (median)
in months
Gerszten et al., [23] Definitive, extended
field IMRT, retrospective
45 Gy and 55 Gy to
involved nodes
25 Gy/5 Gy 22 IB-IIIB 9 (receiving nodal
boost) 2 positive
on surgical staging
11 No data
Kidd et al., [6] Definitive 18 FDG PET
based IMRT, retrospective
comparison with non-IMRT
radiochemotherapy
50 Gy to whole pelvis
and additional 20 Gy
to central region (cervix)
6 weekly fraction
of 6.5 Gy HDR
135 IBI-IVA 41 (30.4 %) 68 (50.4 %) 22 (range, 5–47 months)
Hasselle et al., [25] Definitive IMRT in 81
patients. Retrospective
multicentric study.
median 45 Gy (range:
39.6 - 50.4 Gy)/1.8 Gy
LDR 35 to 40 Gy;
5 HDR fractions
to 27.5 to 30 Gy
111 (22 postop, 8
with consecutive
surgery)
I–IVA No data No data 26.6 (range, 5.4–99.0 months)
Chen et al., [26] Definitive, IMRT,
retrospective
45–54 Gy, (54–60 nodes
simultan boost)
HDR 20 – 33.5
Gy/4–6 Gy/
Fraction 2 x Week
109 IB2 - IVA 14 82 32.5 for survival pts (5–75)
Du XL et al., [29] Definitive RT-CH.
Comparison of
reduced field IMRT with
conventional EBRT.
30 Gy to whole pelvis
with additional boost
of 30 Gy to lymphatic
drainage region as
well as paracervix
and parametrium.
HDR 10–30 Gy/
5–6 Gy SD
60 IIB–IIIB No data No data 7 months (range,
6 - 68 months)
Gandhi et al. [8] Definitive radio
chemotherapy. Nonblind,
prospective, randomized,
phase II trial. Comparison
with whole pelvis
conventional
radiotherapy
50.4 Gy/1.8 Gy 21 Gy/7 Gy SD 22 IIB-IIIB No data No data 21.6 months (range,
7.7-34.4 months).
Jensen LG et al., [31] Definitive, extended-field
intensity-modulated
radiotherapy
45 to 50.4, median
boost dose to
parametrian: 9 Gy
or pelvic LN 10 Gy
in 16 pts, PA boost of
median 10.4 Gy in 6 pts
LDR 35 to 40
Gy 1 or 2 x; HDR
19.8 to 30 3
to 5 x
21 IB1 - IIIB 14 patients had
paraaortic LN and
20 pelvic LN
0 22 (range, 12 to 56 months)
for survived patients
Cihoric et al. [11] Definitive dose escalated
IMRT, retrospective
50.4 to whole pelvis,
5.4 to 9 Gy boost to
central disease, 62 Gy
to lymph nodes
HDR TD 15–18
Gy with 4–6.5
Gy SD
39 IB2 to IVA 24 (61.5 %) 15 36 (3–71 months)
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Table 4 Literature overview
Author and year
of publication
Total number of
patients with
disease relapse
Loco-regional
failure
DFS/patient alive
without sign of disease
OS/alive at
last follow up
Acute gastrointestinal
or genitourinary toxicites
Gr 3 or greater
Chronic gastrointestinal
or genitourinary toxicites
Gr 3 or greater
Normal tissue planning constraints
Gerszten et al., [23] No data No data No data No data 0 Not evaluated rectal maximum dose: 54 Gy with no
more than 40 % of the rectal volume
receiving 40 Gy; bladder maximum
dose 54 Gy with no more than 50 %
at 40 Gy; small bowel maximum 50 Gy
with no more than 35 % of small bowel
receiving 35 Gy.
Kidd et al., [6] 39 11 (8.1 %) 91 (67.4 %) pts No data No data 8 (6 %) <40 % of bowel to receive 30 Gy, <40 %
of rectum to receive 40 Gy, <40 % of
pelvic bones to receive 40 Gy, and <40 %
of femoral heads to receive 30 Gy.
Hasselle et al., [25] No data The 3-year pelvic
failure rate - 29.2 %
69 % (95 % CI,
59–81 %)
78 % (95 %
confidence
interval [CI],
68–88 %)
2 % (95 %
CI, 0–7 %)
7 % (95 % CI,
2–13 %)
rectum: maximum dose < 50 Gy; bowel
V45 < 250 mL, pelvic BM V20 < 75 %,
V10 < 90 %; bladder: as low as
reasonably achievable
Chen et al., [26] 5 (4.6 %)
locoregional
only; 14(12.8 %)
distant only; 29
(26.6 %) in total;
21.9 % at 3 year 67.6 % at 3 year 78.2 % at
3 year
3 pts (GI Only) 5 (4.6 %) GI 7
(6.4 %) GU
rectum: V30 < 50 %; small bowel:
V30 < 15 %;
Du XL et al., [29] 64.90 % No data 64.9 % PFS at 5 y 82.5 % at
3 y; 71.2 %
at 5 y
7 0 No data
Gandhi et al. [8] 5 (22.7 %) 2 (9.1 %) 60 % at 27 months 85.7 % at
27 months
2 0 small bowel: volume receiving 40 Gy
(V40) <32 %, maximum dose <50 Gy;
rectum: V40 < 40 %, maximum
dose <50 Gy; bladder: V40
< 40 %, maximal dose < 50 Gy
Jensen LG et al., [31] 11 No data 42.9 % (95 % CI,
26.2 % Y70.2 %).
At 11 months
59.7 % (95 %
confidence
interval [CI],
41.2 %
Y86.4 %) at
11 months
4(19 %) 2 (9.5 %) rectum: maximum dose < 50 Gy; bowel:
V45 < 250 cm3; bladder: as low as
reasonably achievable.
Cihoric et al. [11] 14 (35.9 %) 9 (23.1 %) patient
with pelvic failure;
LRFS was 55.2 ±
4.4 months
25 (64.1 %). The
mean DFS: 47.2 ±
4.9 months
Mean OS
time for the
entire cohort:
61.1 ± 3.5
months
2 (5.2 %) 2 (5.2 %) 60 % of rectum < 50 Gy, 35 % of
bowel < 35Gy, 50 % of bladder < 50
Gy and 10 % of the femoral
heads < 50 Gy.
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for failure cannot be precisely determined in this
moment. Several potential factors, such as tumor
resistance, geographical miss or insufficient dose, are
stated in literature. In our cohort potential reason for
local failure can be insufficient brachytherapy dose. In
early stages of IMRT technique adoption we were
cautious due to potential excess of toxicity due to
escalated external beam dose. Our median summed
EQD2 dose was 77.1 Gy (calculated using the formula:
EQD2 = BED/(1 + 2/α/β), where BED = ED* (1 + ED/α/β)
and α/β = 10). At the time of our protocol development
there were not much data about combined escalated
dose EBRT with HDR BT. However, this dose may be
not sufficient for treatment of bulky tumors. Due to
findings of our interim institutional analysis we chan-
ged policy and from 2011 onwards our dose prescrip-
tion for HDR brachytherapy was 4 × 6 Gy prescribed
to high risk tumor volume as defined by GEC-ESTRO
guideline [12].
Further possible reasons for therapy failure are
geographical miss or failure to detect gross disease,
either local or nodal, and irradiate with sufficient
dose. Although we used three imaging modalities
including clinical evaluation, it is possible that we did
not succeed to recognize all area needed to be irradi-
ated with high dose. Every imaging modality has some
limitation to detect local or nodal disease. However,
the most appropriate staging is a topic of an ongoing
debate. Although, surgical staging is more reliable
than CT based staging and several retrospective
studies have shown an advantage of surgical node
extirpation, there is still no high level evidence to
incorporate surgical staging or therapy of bulky
lymph nodes into clinical practice. This must be
observed in the context of more advanced imaging
and radiotherapy techniques. Although not perfect,
PET-CT appears to be a valid addition to clinical
staging of patients with cervical cancer [33, 34]. Extensive
lymphadenectomy combined with radio chemotherapy
may be connected with excess toxicity and bulky lymph
nodes may be treated with advanced IGRT technique
[11]. Prospective clinical trials are required to answer
this questions.
Even though, lymph node involvement is one of
the most important prognostic factors in cancer,
evaluation and staging is not well defined in cervical
cancer patients [35]. In addition several questions
remain open regarding planning volumes and up to
date there is still no clear concept regarding nodal
PTV. A recent retrospective analysis of 665 primarily
operated patients, revealed 168 patients with nodal
metastases, with the most common site of occur-
rence, being the obturator and iliacal nodal stations,
were affection of other nodal region was rare. These
findings may help for further future optimization of
the PTV [36].
Almost all patients with a loco-regional failure have a
systemic failure as well. It is still unclear, whether meta-
static cancer cells are already present at the time of
therapy begin or if they are a result of seedling from
tumor recurrence. A potential therapeutic answer for
the treatment of microscopic systemic disease and at the
same time, for a better loco-regional control, could be
the introduction of an additional chemotherapeutic agent
to cisplatin. Duenas-Gonzales et al. showed encouraging
results, by combining gemcitabine with cisplatin, but a
broader adoption of that concept was abandoned, as a
result of the higher incidence of toxicities [37]. A dual
chemotherapy concept should be evaluated in the future,
together with IMRT as radiation delivery method.
It should also be noted that our study has several limi-
tations. The small patient cohort prevents us from
reaching a valid statistical conclusion in regards to
possible risk factors and the therapy outcome. At the
same time, there is no comparison to an additional arm
comparing a different treatment dose. Furthermore, our
cohort is heterogeneous, with some of our patients being
partially operated prior to administering chemoradiation.
Late toxicities of the proposed treatment concept are
also an important issue. Late gastrointestinal toxicities
occur in ca. 10 % of all patients and most occur within
the first two years, but can still emerge up to 20 years
after treatment. The urological toxicities can rise up to
10 % and their incidence can increase over time. Our
relatively short follow-up is limited in the detection of
potential late toxicities [38].
We managed to show that the intensified radiation
therapy is well tolerated by patients with advanced
cervical cancer; however we could not show survival
benefit, potentially as a result of our small patient
cohort. Therefore, the results of this study have to
be validated on a larger patient cohort in order to
show its impact on recurrence rate and survival.
Nevertheless, our study can be used for new treat-
ment strategies for patients with loco-regionally
advanced cervical cancer.
Conclusion
Patients with loco-regionally advanced cervical cancer
treated with intensified IMRT seem to have a satisfac-
tory outcome with reasonably low levels of treatment
related toxicities. Although being limited due to its
small size and retrospective nature, the present study
contributes to the notion that the application of a high
dose of radiation in the pelvic region by means of
IMRT is feasible, with an acceptable profile of un-
wanted events and good loco-regional control, compar-
able with other published studies.
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